SSI Diagnostica acquires American Covid-19 front-runner
In august 2020, SSI Diagnostica acquires CTK Biotech, which, among other things, develops and distributes diagnostic rapid tests. CTK Biotech is headquartered in San Diego and has production in Beijing and covers markets in Latin America, Asia and Africa, which means that SSI Diagnostica can now, together with CTK Biotech, reach patients and customers in most of the world.
“CTK Biotech are very skilled in developing new products, and their production equipment is simply excellent, with high efficiency and quality. Furthermore, our common, global distribution network will be very strong”, says CEO, Søren Skjold Mogensen, as some of the reasons for the acquisition.
With the acquisition of CTK Biotech, a new diagnostics powerhouse is created with international weight and with a focus on rapid diagnostic tests within infectious diseases. The new, combined company will have strong competencies in production, research & development, and international distribution.